Format

Send to

Choose Destination
Pigment Cell Melanoma Res. 2015 Jul;28(4):417-30. doi: 10.1111/pcmr.12376. Epub 2015 May 6.

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
2
Breast Medical Oncology Group, Yale University School of Medicine, New Haven, CT, USA.
3
Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.

Abstract

BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor treatment. We have found that BRAF-mutant melanoma cell lines are more sensitive than wild-type BRAF cells to the small molecule tyrosine kinase inhibitor dovitinib. Sensitivity is associated with inhibition of a series of known dovitinib targets. Dovitinib in combination with several agents inhibits growth more effectively than either agent alone. These combinations inhibit BRAF-mutant melanoma and colorectal carcinoma cell lines, including cell lines with intrinsic or selected BRAF inhibitor resistance. Hence, combinations of dovitinib with second agents are potentially effective therapies for BRAF-mutant melanomas, regardless of their sensitivity to BRAF inhibitors.

KEYWORDS:

MEK inhibitor; combination therapy; dovitinib; mutant BRAF; vemurafenib resistance

PMID:
25854919
PMCID:
PMC5215495
DOI:
10.1111/pcmr.12376
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center